Hopkins Janet Jill 4

4 · Aura Biosciences, Inc. · Filed Mar 3, 2026

AI-generated summary of this filing

Updated Mar 3, 2026

Aura Biosciences (AURA) CMO Janet Hopkins Receives RSU & Option Awards

What Happened

Janet Jill Hopkins, Chief Medical Officer of Aura Biosciences (AURA), received awards on 2026-03-02 totaling 250,000 shares: 89,056 restricted stock units (RSUs) and 160,944 derivative/option-based units. Both grants were reported at $0.00 per share (no cash paid on grant).

Key Details

Transaction date(s): 2026-03-02; filing date: 2026-03-03 (Form 4) — appears timely.
Price: $0.00 per share for both awards (standard for compensation grants).
Grant breakdown: 89,056 RSUs; 160,944 derivative/option-based shares — total 250,000.
Vesting (footnotes):
- RSUs (89,056): vest in four substantially equal annual installments beginning January 15, 2027, subject to continued service.
- Option-based shares (160,944): 25% vest on February 1, 2027; remaining 75% vests pro rata over the following 36 months, subject to continued service.
Shares owned after transaction: not disclosed in the provided details.
Transaction code: A = Award/Grant (compensation), not an open-market purchase or sale.

Context

These awards are compensation grants intended as long-term incentives and do not represent an immediate market purchase or sale. The option-based award must vest before any exercise; nothing in this filing indicates exercise or sale of shares. Compensation grants are common for executives and should be viewed as part of pay/retention programs rather than a direct endorsement to buy or sell stock.

Form 4

Period: 2026-03-02

Chief Medical Officer

Transactions

Award
Common Stock
[F1]
2026-03-02+89,056→ 321,340 total
Award
Stock Option (Right to Buy)
[F2]
2026-03-02+160,944→ 160,944 total
Exercise: $6.14Exp: 2036-03-02→ Common Stock (160,944 underlying)

Footnotes (2)

[F1]These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
[F2]The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Signature

/s/ Conor Kilroy, as Attorney-in-Fact|2026-03-03

1 file